Reported Earlier, Bayer’s SUNHARBO Receives FDA Approval As First Factor XIa Inhibitor, Reducing Ischemic Stroke 6.2% Versus 8.4% For Placebo In 12,327-Patient Phase 3 OCEANIC-STROKE Study

Benzinga
Open on Benzinga